Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan.
To evaluate the efficacy of imatinib in a practical setting, we registered 43 patients with newly diagnosed chronic myelogenous leukemia (CML) (group I) and 56 patients with previously diagnosed CML (group II) at 11 hematology centers in Nagasaki prefecture, Japan, from December 2001 to July 2005 and analyzed the molecular responses. Cytopenia, fluid retention, and skin rash were major adverse events, along with elevation in creatine phosphokinase levels. With a follow-up of approximately 3.5 years, imatinib treatment led to 88.7% overall survival (OS) and 85.2% progression-free survival (PFS) rates for group I, and 79.8% OS and 76.6% PFS rates for group II; the rates were not significantly different despite a lower average imatinib dose in group II. The rates of complete cytogenetic response at 30 months and major molecular response at 24 months were 86.1% and 62.5%, respectively, in group I, and 77.9% and 58.3% in group II; the rates were not significantly different. As has been reported by other groups, these results demonstrate that imatinib treatment can provide excellent clinical and molecular effects for not only newly diagnosed but also previously treated CML patients in practical settings that cover a wider variety of patients than clinical trials.
Matsuo
Emi
E
Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Miyazaki
Yasushi
Y
Tsutsumi
Chizuko
C
Inoue
Yoriko
Y
Yamasaki
Reishi
R
Hata
Tomoko
T
Fukushima
Takuya
T
Tsushima
Hideki
H
Imanishi
Daisuke
D
Imaizumi
Yoshitaka
Y
Iwanaga
Masako
M
Sakai
Mari
M
Ando
Koji
K
Sawayama
Yasushi
Y
Ogawa
Daisuke
D
Kawaguchi
Yasuhisa
Y
Nagai
Kazuhiro
K
Tsukasaki
Kunihiro
K
Ikeda
Shuichi
S
Moriuchi
Yukiyoshi
Y
Yoshida
Shinichiro
S
Honda
Miyuki
M
Taguchi
Jun
J
Onimaru
Yasuyuki
Y
Tsuchiya
Takeshi
T
Tawara
Masayuki
M
Atogami
Sunao
S
Yamamura
Masaomi
M
Soda
Hisashi
H
Yoshida
Yoshiharu
Y
Matsuo
Yuji
Y
Nonaka
Hiroaki
H
Joh
Tatsuro
T
Takasaki
Yumi
Y
Kawasaki
Chiyuki
C
Momita
Saburo
S
Jinnai
Itsuro
I
Kuriyama
Kazutaka
K
Tomonaga
Masao
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001549:Benzamides; D003402:Creatine Kinase / Q000097:blood; D020732:Cytogenetic Analysis; D018572:Disease-Free Survival; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D007564:Japan; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D012074:Remission Induction
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D003402:Creatine Kinase